Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder resulting from the neoplastic transformation of the primitive hematopoietic stem cell. It is one of the rarest forms of leukemia in terms of annual incidence and accounts for 10 percent to 15 percent of all incident leukemia cases. However, it is anticipated to become the most widespread hematologic disorders in the globe by 2022. CML is an increasingly attractive market opportunity given the transformational impact of targeted therapies on disease progression and survival; the prevalence of CML is now increasing as patients now have a normal lifespan and no longer die shortly after diagnosis, and due to the aging population. The main unmet needs in CML are overcoming TKI resistance and addressing patients with accelerated or blast phase disease. At Present, existing BCR-ABL inhibitors form the stronghold of CML treatment comprises first-generation imatinib and more effective second-generation BCR-ABL inhibitors nilotinib and dasatinib, with ponatinib and bosutinib having been lately approved for market inclusion.
Our reports have been used by over 10K customers, including:
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.
The global IV and oral iron drugs market is expected to grow due to the prevalence...
Autism (Central Nervous System) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Autism - Drugs in Development, 2021, provides an overview of the Autism (Central Nervous System) pipeline landscape. Autism, also known as complex developmental...
Community Acquired Pneumonia (Infectious Disease) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Drugs in Development, 2021, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Drugs in Development, 2021 Summary Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and...
Hepatic Encephalopathy (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Drugs in Development, 2021, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape. Hepatic...
272 pages •
By The Business Research Company
• Mar 2021
Antisense & RNAi Therapeutics Global Market Opportunities And Strategies To 2030: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global antisense & RNAi therapeutics market. Description: Where is the largest and fastest growing...
The global cancer cachexia market was valued at USD 2,256.35 million in 2020, and it is expected to reach USD 2,974.49 million by 2026, registering a CAGR of 4.47% during the forecast period. The outbreak of COVID-19 impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing...
Therapy
World
Europe
APAC
South America
Middle East
Africa
Cancer Incidence
Cancer Mortality
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.